Back

Pooled on treatment lipid lowering efficacy of the CETP inhibitor obicetrapib in phase III trials

30 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Lipid lowering and cardiovascular outcomes Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Mathijs De Kleer

Academic Medical Centre, Amsterdam (Netherlands (The))

6 More presentations in this session

Presentation thumbnail
Gender-related differences in efficacy, safety and adherence of PCSK9 inhibitors in real-world clinical practice: insights from the AT-TARGET-IT Registry
Professor P. Perrone-Filardi (Naples, IT)
Abstract
Presentation thumbnail
Sustained combination lipid-lowering therapy determines durability of LDL-C <55 mg/dL after ACS: a structured implementation study (2022–2026)
Doctor K. Mahajan (Mandi, IN)
Abstract
Presentation thumbnail
EDP167, an ANGPTL3-target siRNA, showed favorable safety and lipid-lowering potential in Chinese healthy adult volunteers and subjects with mild dyslipidemia
Doctor B. Jiang (Hangzhou, CN)
Abstract
Presentation thumbnail
Statin therapy and 1-year mortality in non-ischaemic acute myocardial injury: a dual-cohort study
Doctor T. Yang (Tianjin, CN)
Abstract
Presentation thumbnail
Effect of apolipoprotein B reduction on major adverse cardiovascular events in randomized controlled trials of triglyceride-lowering therapies: systematic review and exploratory meta-regression
Doctor M. Sobral Domingues (Lisbon, PT)
Abstract

Access the full session

Session thumbnail
Lipid lowering and cardiovascular outcomes

The Event

Event poster

ESC Congress 2026

30 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Obicetrapib and cardiovascular events
1 September 2025
thumbnail
Congress Presentation
Age-stratified analysis of real-world lipid-lowering therapy use and LDL-C goal attainment at 1-year follow-up: insights from the European SANTORINI study
1 September 2025
thumbnail
Congress Presentation
RNA interference targeting apolipoprotein C-III with ARO-APOC3 in healthy volunteers mimics lipid and lipoprotein findings seen in subjects with inherited apolipoprotein C-III deficiency
31 August 2020
thumbnail
Congress Presentation
Impact of bempedoic acid alone and combined with ezetimibe on ldl-cholesterol reduction: graphical evidence and retrospective analysis of a real-world clinical cohort
24 April 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources